Iterum Therapeutics (ITRMF)
OTHER OTC:ITRMF
ITRMF Stock Chart & Stats
$0.34
-$0.04(-2.14%)
At close: 4:00 PM EST
$0.34
-$0.04(-2.14%)
Day’s Range― - ―
52-Week Range$0.01 - $1.42
Previous CloseN/A
VolumeN/A
Average Volume (3M)813.22K
Market Cap
$591.75K
Enterprise Value$23.33M
Total Cash (Recent Filing)$11.00M
Total Debt (Recent Filing)$33.73M
Price to Earnings (P/E)―
Beta2.04
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding52,835,200
10 Day Avg. Volume1,119,323
30 Day Avg. Volume813,222
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-8.54
Price to Sales (P/S)0.00
P/FCF Ratio-1.30
Enterprise Value/Market Cap39.42
Enterprise Value/Revenue59.82
Enterprise Value/Gross Profit-34.92
Enterprise Value/Ebitda-1.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$9.38M
Bulls Say, Bears Say
Bulls Say
Clinical AdvantageLate‑stage trials demonstrating superiority to conventional antibiotics and a broad‑spectrum mechanism against resistant pathogens may drive guideline consideration and formulary inclusion.
Regulatory PositioningORLYNVAH's approval as an oral penem for adult women with uncomplicated urinary tract infections provides an option when few oral alternatives exist, supporting clinician adoption of a non‑injectable therapy.
Unique Oral OfferingBeing the only orally available penem for uncomplicated urinary tract infections creates a differentiated commercial position that can sustain uptake even with smaller commercialization partners.
Bears Say
Commercial Performance And Dilution RiskModest reported sales combined with sharp share declines after adverse announcements increase pressure to raise capital, heightening the likelihood of dilutive financings that could hurt shareholder value.
Corporate SolvencyFiling to begin winding up procedures in Ireland due to limited cash, inability to raise non‑dilutive capital, and lack of acceptable strategic partners signals severe liquidity strain that could interrupt operations.
Exchange Listing RiskA Nasdaq delisting notice for failure to meet minimum bid and market value requirements raises the real risk of removal from the exchange and reduced investor access.
ITRMF FAQ
What was Iterum Therapeutics’s price range in the past 12 months?
Iterum Therapeutics lowest stock price was $0.01 and its highest was $1.42 in the past 12 months.
What is Iterum Therapeutics’s market cap?
Iterum Therapeutics’s market cap is $591.75K.
When is Iterum Therapeutics’s upcoming earnings report date?
Iterum Therapeutics’s upcoming earnings report date is May 20, 2026 which is in 41 days.
How were Iterum Therapeutics’s earnings last quarter?
Iterum Therapeutics released its earnings results on Mar 12, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.145 by -$0.055.
Is Iterum Therapeutics overvalued?
According to Wall Street analysts Iterum Therapeutics’s price is currently Overvalued.
Does Iterum Therapeutics pay dividends?
Iterum Therapeutics does not currently pay dividends.
What is Iterum Therapeutics’s EPS estimate?
Iterum Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Iterum Therapeutics have?
Iterum Therapeutics has 52,835,200 shares outstanding.
What happened to Iterum Therapeutics’s price movement after its last earnings report?
Iterum Therapeutics reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.145. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Iterum Therapeutics?
Currently, no hedge funds are holding shares in ITRMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Iterum Therapeutics
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics plc is in reorganization.
ITRMF Earnings Call
Q3 2025
0:00 / 0:00
ITRMF Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Cel-Sci
―
Clene
―
Xilio Therapeutics
―
CAMP4 Therapeutics Corporation
―
Radiopharm Theranostics Limited Sponsored ADR
―
Ownership Overview
0.46% Insiders
0.02% Mutual Funds
1.82% Other Institutional Investors
97.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---